CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 39 enrolled
Drug / intervention
V920 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02280408
NCT02280408Phase 1Completed
CompareCT.gov

A Phase 1 Randomized, Double-Blind, Placebo Controlled, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of Prime-Boost VSV Ebola Vaccine in Healthy Adults

Merck Sharp & Dohme LLC·interventional·Posted Oct 31, 2014·Updated Jul 12, 2019

In Brief

A Phase 1 clinical trial evaluating Placebo and V920 for Ebola Viruses. Completed, enrolled 39 participants.

Detailed Summary

Ebola virus has infected and killed people, mostly in Africa. In 2014, the Zaire ebolavirus (ZEBOV) has affected several thousand people. There is no approved effective way to treat or prevent Ebola. Researchers are trying to develop a vaccine for it. This is a study of the anti-Ebola vaccine vesicular stomatitis virus (VSV) ZEBOV (V920; BPSC-1001) to see if it is safe and to see how it affects people's immune system.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEbola Viruses
Countries--
CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID), BioProtection Systems Corporation

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 31, 2014
Enrollment StartOct 7, 2014
Primary CompletionDec 10, 2015
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 11.7 years ago

Interventions

Placeboother

Normal saline placebo.

V920biological

Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10\^6, 2x10\^7, or 1x10\^8 pfu.